DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Up 5.1% Today

What is DENTSPLY SIRONA Inc.?

DENTSPLY SIRONA (XRAY) is a company specializing in dental solutions for healthcare professionals globally. XRAY exhibited strong bullish movement in the market today.

Why is DENTSPLY SIRONA Inc. going up?

XRAY stock is up 5.1% on Jun 24, 2026 15:21

• The appointment of John C. Fortson as CFO and Executive Vice President is seen positively by investors, possibly contributing to the bullish movement.
• Director Jonathan Jay Mazelsky's recent purchase of 10,000 shares at a time when the stock is near its 52-week low suggests confidence in the company's future.
• The company's Q1 2026 financial performance showed mixed results, with revenue exceeding expectations while EPS fell short. This mixed performance might have influenced market sentiment, but the overall undervaluation narrative and dividend yield supported the bullish trend.
• Lindi Rene Barton-Brobst's significant holdings, including shares and stock options, indicate insider confidence in the company's long-term growth potential, further boosting investor sentiment.

XRAY Price Chart

XRAY Technical Analysis

XRAY News

DENTSPLY SIRONA (XRAY) Stock Could Be 78% Undervalued After CFO Appointment

DENTSPLY SIRONA (XRAY) is back in focus after appointing John C. Fortson as CFO and Executive Vice President, a change that could influence investor perception. Despite recent share price declines, the stock is considered 78% undervalued by one narrative, suggesting a fair value of $45.50 compared to its current price of $10.03, based on recurring dental demand and resilient margins. Investors are encouraged to review figures and evaluate potential upsides, especially given the company's current loss-making status.

https://www.sahmcapital.com/news/content/dentsply-sirona-xray-stock-could-be-78-undervalued-after-cfo-appointment-2026-06-18

Dentsply Sirona director Jonathan Mazelsky buys $101,400 in shares

Jonathan Jay Mazelsky, a director at DENTSPLY SIRONA Inc. (NASDAQ:XRAY), recently purchased 10,000 shares of the company's common stock for $101,400. This open market purchase comes as the stock trades near its 52-week low and offers a 6.2% dividend yield. The company also reported mixed Q1 2026 financial results with revenue beating expectations but EPS falling short, alongside an expanded distribution agreement.

https://m.uk.investing.com/news/insider-trading-news/dentsply-sirona-director-jonathan-mazelsky-buys-101400-in-shares-93CH-4736520?ampMode=1

Dentsply Sirona (XRAY) SVP details stock, RSU, phantom and option holdings

Dentsply Sirona Inc.'s SVP, GC & Secretary, Lindi Rene Barton-Brobst, filed an initial statement of beneficial ownership (Form 3) detailing her holdings. The filing shows direct ownership of 45,185.444 shares of common stock, including 38,743.444 Restricted Stock Units, and 254.6498 indirectly held shares in a 401(k) plan. She also holds phantom stock units and multiple stock options with varying exercise prices and expiration dates, none of which indicate recent buying or selling activity.

https://www.stocktitan.net/sec-filings/XRAY/form-3-dentsply-sirona-inc-initial-statement-of-beneficial-ownership-ec3c3e683fe7.html

Dentsply Sirona director Jonathan Mazelsky buys $101,400 in shares

Dentsply Sirona director Jonathan Mazelsky recently purchased 10,000 shares of the company's common stock for $10.14 per share, totaling $101,400. This transaction occurred while the stock is near its 52-week low, and InvestingPro analysis suggests the company is undervalued, offering a 6.2% dividend yield. Dentsply Sirona also reported mixed Q1 2026 financial results with revenue beating expectations but EPS falling short, alongside an expanded distribution agreement.

https://www.investing.com/news/insider-trading-news/dentsply-sirona-director-jonathan-mazelsky-buys-101400-in-shares-93CH-4751108

Dentsply Sirona (XRAY) director amends Form 4 to show share purchase

Dentsply Sirona director Jonathan Jay Mazelsky filed an amended insider report (Form 4/A) to clarify a prior transaction. The amendment specifies that his purchase of 10,000 shares of common stock at $10.14 per share was an open-market acquisition, correcting an earlier mistaken report that coded it as an award. Following this transaction, Mazelsky's direct ownership in Dentsply Sirona now totals 61,668.534 shares.

https://www.stocktitan.net/sec-filings/XRAY/form-4-a-dentsply-sirona-inc-amended-insider-trading-activity-5860ba2542e2.html

Trending Today

Cardano ($ADA) Crypto Forecast: Up 5.1% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 10.0% Today

Uber Technologies Inc. ($UBER) Stock Forecast: Up 5.3% Today

Texas Instruments Incorporated ($TXN) Stock Forecast: Down 5.1% Today

Keysight Technologies Inc. ($KEYS) Stock Forecast: Down 7.5% Today

Stryker Corporation ($SYK) Stock Forecast: Up 5.1% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Up 6.7% Today

Salesforce.com Inc ($CRM) Stock Forecast: Up 5.5% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Down 7.3% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.5% Today

DENTSPLY SIRONA Inc. Price History

19.04.2026 - XRAY Stock was down 5.0%

• Dentsply Sirona Inc (XRAY) faced a decline in its stock price today along with healthcare stocks in general.
• Recent data from the April PPI report highlighted a rise in wholesale inflation, especially in the service sector. This increase could lead to higher operating costs for healthcare providers and raise concerns about drug pricing regulations.
• Although Dentsply Sirona exceeded revenue expectations in Q1 2026, its adjusted EPS fell short of estimates, contributing to the negative market sentiment.
• The interplay of economic challenges, uncertainties around regulations, and earnings results likely influenced XRAY’s stock performance today. This situation may present opportunities for investors interested in long-term growth within the dental sector.

24.05.2026 - XRAY Stock was up 5.1%

• The appointment of John C. Fortson as CFO and Executive Vice President is seen positively by investors, possibly contributing to the bullish movement.
• Director Jonathan Jay Mazelsky's recent purchase of 10,000 shares at a time when the stock is near its 52-week low suggests confidence in the company's future.
• The company's Q1 2026 financial performance showed mixed results, with revenue exceeding expectations while EPS fell short. This mixed performance might have influenced market sentiment, but the overall undervaluation narrative and dividend yield supported the bullish trend.
• Lindi Rene Barton-Brobst's significant holdings, including shares and stock options, indicate insider confidence in the company's long-term growth potential, further boosting investor sentiment.

16.05.2026 - XRAY Stock was up 5.8%

• Positive sentiment surrounds DENTSPLY SIRONA (XRAY) due to recent insider buying activities:
• Directors Brian Gladden, Jonathan Jay Mazelsky, and Brian P. McKeon have shown confidence in the company's future prospects through significant stock purchases.
• The appointment of John C. Fortson as the new CFO is seen as a contributing factor to the bullish trend:
• Investors believe Fortson can positively impact capital allocation, strategy, and financial performance, potentially driving growth.
• Investor confidence in DENTSPLY SIRONA (XRAY) has been further strengthened by expanded distribution partnerships, reaffirmed 2026 net sales guidance, and other developments, leading to the recent bullish market movement.

08.04.2026 - XRAY Stock was down 5.2%

• A reduction in DENTSPLY SIRONA's price target to $14 from $16 by Mizuho, highlighting ongoing margin constraints and market softness, likely influenced the stock's decline.
• The company's Q1 earnings call transcript, which exposed an EPS shortfall and external pressures, despite efforts to implement a "return to growth" strategy, could have further eroded investor confidence.
• The timely and effective execution of the company's growth and restructuring plan is imperative in restoring investor trust and market stability, as noted in the discourse surrounding the company.
• The company's Q1 2026 net loss, amplified research and development expenditures, restructuring outlays, and legal hurdles suggest a phase of strategic adaptations and intensified operational focus, possibly exerting a negative influence on investor sentiment and stock performance.

29.04.2026 - XRAY Stock was up 5.4%

• Experienced a bullish movement today.
• Increase in earnings estimates by Zacks Research, despite a recent earnings miss, indicates growing confidence in the company's financial performance.
• Expansion of distribution partnerships with Nashville Dental reflects strategic focus on enhancing customer accessibility and driving the adoption of digital dental solutions.
• Institutional investors increasing their positions and company insiders making significant purchases suggest a positive sentiment towards the stock, contributing to its bullish movement.

15.04.2026 - XRAY Stock was down 5.7%

• The decline in Dentsply Sirona's stock (XRAY) today is linked to the earnings miss in Q1, despite surpassing revenue expectations.
• The market's negative response to the revised FY guidance is due to the company reducing its EPS outlook for the full year, suggesting potential challenges ahead.
• A rise in wholesale inflation to 6% annually as shown in the April PPI report has impacted healthcare companies like Dentsply Sirona, increasing operating costs and raising concerns about possible regulatory actions on drug pricing.
• Despite a significant drop in the stock price over the past year, assessments of the company's value indicate Dentsply Sirona may be undervalued, offering a different perspective on its future prospects.

22.04.2026 - XRAY Stock was up 5.0%

• The bullish movement in Dentsply Sirona's stock today could be attributed to the company's participation in the upcoming 2026 Stifel Jaws & Paws Conference, where management will discuss recent results and market trends.
• Despite recent setbacks in share price and earnings, an analysis indicating the company being undervalued by 78.4% might have sparked investor interest and contributed to the positive market movement.
• The registration opening for the reimagined DS World Las Vegas event, focusing on practical learning and innovations in connected dentistry, could have also generated optimism among investors about the company's future prospects.
• Dentsply Sirona's Q1 2026 results showing modest growth in digital dentistry and specialty products, along with reaffirmation of full-year guidance, likely instilled confidence in investors, leading to the bullish market movement.

13.04.2026 - XRAY Stock was down 5.1%

• UBS Group AG and First Eagle Investment Management LLC have increased their holdings in DENTSPLY SIRONA Inc., displaying confidence in the firm's long-term viability.
• Vanguard Group Inc. has scaled back its position in the company, potentially indicating a more cautious stance on XRAY's future performance.
• The company's recent financial results, with earnings per share slightly lower than anticipated but revenue surpassing expectations, may have influenced the bearish sentiment as investors evaluate its growth prospects.
• The differing viewpoints on DENTSPLY SIRONA's valuation and future prospects could have contributed to market uncertainty, leading to the downward movement in the stock.

17.05.2026 - XRAY Stock was up 5.6%

• The bullish movement in XRAY today can be attributed to significant insider buying activity, with directors Clyde Hosein and Brian Gladden purchasing substantial amounts of common stock.
• The confidence shown by insiders through these purchases, despite the stock trading near its 52-week low, likely boosted investor sentiment and contributed to the bullish trend.
• The undervalued status of the stock, as suggested by analysis, along with the 6.12% dividend yield, might have attracted investors looking for potential value opportunities in the market.
• The combination of insider buying, undervaluation, and dividend yield could have acted as catalysts for the bullish movement in XRAY today.

28.04.2026 - XRAY Stock was up 5.7%

• Earnings estimates for Dentsply Sirona were raised to $0.37 from $0.36, and institutional investors increased their positions in the stock. This likely boosted investor confidence in the company's future prospects.
• The expansion of the distribution deal with Nashville Dental across a nine-state territory aligns with Dentsply Sirona's strategy to improve customer accessibility and drive technology adoption, potentially leading to increased revenue in the future.
• Despite an ongoing investigation into potential claims against Dentsply Sirona for inflated revenue and earnings, positive news surrounding the company's partnerships and financial performance overshadowed these concerns, contributing to the stock's bullish movement today.

04.04.2026 - XRAY Stock was down 3.4%

• The bearish movement in XRAY stock today could be attributed to several factors:
• Despite being viewed favorably by Ariel Investments and analysts, the recent price target cut from $15 to $13 might have raised concerns among investors.
• The slight miss on quarterly EPS, coupled with the company setting FY2026 EPS guidance lower than expected, could have led to a loss of confidence in XRAY's short-term performance.
• The significant passive investment stake held by Vanguard, while indicating long-term commitment, might have also created uncertainty in the market, contributing to the bearish trend.
• Overall, the market sentiment towards XRAY today seems to have been influenced by a combination of financial performance, analyst ratings, and institutional ownership, leading to the bearish movement in the stock.

09.05.2026 - XRAY Stock was up 5.2%

• The inclusion of digital dentistry technologies within Nashville Dental Inc.'s offerings and the extension of a partnership with Patterson Dental are viewed as favorable developments in expanding access to DENTSPLY SIRONA's products, potentially leading to increased sales and revenue.
• The notable rise in ownership stake by Cibc World Market Inc. and other institutional investors indicates confidence in the company's future outlook, despite recent challenges such as sluggish growth and tariff pressures.
• The issuance of Restricted Stock Units (RSUs) to directors Leslie F. Varon, Brian T. Gladden, and Michael J. Barber demonstrates a commitment to aligning interests with shareholders and driving performance, potentially contributing to the stock's upward movement.
• Analysts' conservative "Hold" recommendation and a slight earnings shortfall by the company could be factors influencing the stock's bullish trend, underscoring the importance of closely monitoring future financial performance.